Reach Us
Niir Project Consultancy Services (NPCS)
AN ISO 9001 : 2015 CERTIFIED COMPANY
106-E, Kamla Nagar,Opposite Spark Mall,
New Delhi-110007, India.
Email: npcs.ei@gmail.com,
info@entrepreneurindia.co
Tel: 91-11-23843955, 23845654, 23845886, +91-8800733955
Mobile: +91-9811043595
Fax: 91-11-23845886
Web: www.entrepreneurindia.co
  • Join Us On
Reach Us
Quick Enquiry
 
   
   
 
Quick Enquiry
 
 

Niir Project Consultancy Services (NPCS) through its network of project consultants in a wide range of business and technological disciplines is engaged in providing services to its clients by way of preparation of project reports. We provide the pre-investment information and business plans required for promoters, business leaders, young entrepreneurs, women entrepreneurs, investors, NRI (Non Resident India), startups, professionals looking to start their own venture. The comprehensive project profile reports cover all the aspects of business, from analyzing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. the scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet, break-even point, rate of return (ROR), etc. the DPR is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitized data bank.


Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit

Capacity 0 Plant and Machinery cost 0.00 Lakhs
Working Capital 0.00 Rate of Return (ROR) 0.00 %
Break Even Point (BEP) 0.00 % TCI 0.00 Lakhs
Cost of Project 0.00Lakhs

Description:

 

Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit. Govt Announces Rs. 13,760-Cr Package to Boost API & Medical Device Production in India.

Active Pharmaceutical Ingredient (API)

API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.

Role of Government towards API

The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports.

On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.

The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.

Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.

Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs.

Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates,

The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in India.

Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.

The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years.

Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks

Union Cabinet scheme on Promotion of Bulk Drug Parks

• The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.

• Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.

Related videos: - Manufacturing Business Ideas in Pharmaceutical Industry

Manufacturing of Pharmaceutical Bulk Drugs and Medicine

Pharmaceutical Pellets and Granules

Pharmaceutical Manufacturing Unit

Indian Pharma Industry: An Investment Opportunity

Manufacturing Business Ideas in Pharmaceutical Industry

 

Details:

Promotion of Bulk Drug Parks

• Decision is to develop 3 mega Bulk Drug parks in India in partnership with States.

• Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.

• Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.

• A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.

Production Linked Incentive Scheme

• Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.

• Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.

• Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs.

• A sum of Rs. 6,940 crore has been approved for next 8 years.

List of APIs Products Identified

1)       Amoxicillin

2)       Azithromycin

3)       Erythromycin Stearate/Estolate

4)       Ceftriaxone

5)       Cefoperazone

6)       Cefixime

7)       Cephalexin

8)       Piperacillin  Tazobactam

9)       Sulbactam

10)     Dexamethasone

11)     Prednisolone

12)     Metformin

13)     Gabapentin

14)     Rifampicin

15)     Vitamin B1

16)     Vitamin B6

17)     Clindamycin phosphate

18)     Clindamycin HCL

19)     Streptomycin

20)     Neomycin

21)     Gentamycin

22)     Doxycycline

23)     Potassium clavulanate

24)     Oxytetracycline

25)     Tetracycline

26)     Clarithromycin

27)     Betamethasone

28)     Ciprofloxacin

29)     Losartan

30)     Telmisartan

31)     Artesunate

32)     Norfloxacin

33)     Ofloxacin

34)     Metronidazole

35)     Sulfadiazine

36)     Levofloxacin

37)     Meropenem

38)     Paracetamol

39)     Tinidazole

40)     Ornidazole

41)     Ritonavir

42)     Diclofenac Sodium

43)     Aspirin

44)     Levetiracetam

45)     Carbidopa

46)     Levodopa

47)     Carbamazepine

48)     Oxcarbazepine

49)     Valsartan

50)     Olmesartan

51)     Atorvastatin

52)     Acyclovir

53)     Lopinavir

 

Market in India

The Indian pharmaceutical industry is ranked third in the world in terms of production volume and 13th in terms of domestic consumption value. The Indian pharmaceutical industry size is estimated at US$25 billion in 2015. Formulations account for 65% and bulk drugs for the balance 35% in value terms. The industry is expected to reach US$55 billion by 2020. Bulk drug exports are expected to grow the fastest at 14-16% CAGR due to the growing demand of generic products and rising cost pressures that innovators face. Formulation exports are also expected to grow at 14-16% CAGR.

API manufacturers in India are making efforts to strengthen their marketing capacity in the regulated markets by improving production yields, modifying production processes, and increasing sales in the international markets. More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of API in India was valued at approximately US$ 11 Billion in FY 2016. This market is forecasted to grow at a CAGR of around 9% during the period of FY 2016–FY 2022. Of the total domestic consumption, approximately 32% was imported. Of the total imports, China alone accounts for 57-60% of the APIs imported by India. The remaining imports are from countries such as Italy, Germany, Malaysia, and others. These facts indicate that there is plentiful scope for the domestic API market to grow, if the manufacturers are able to produce the required amount of APIs on their own, rather than importing it from other countries.

Indian API Domestic Consumption

The Indian API domestic consumption market will grow at a CAGR of around 10% from FY 2016 to FY 2022. Furthermore, the government is also taking various initiatives, such as allocating lands in various states for the development of API Mega Parks, increased investment in R&D, etc. to boost the industry. These initiatives will further propel the growth of the Indian API industry, as well as the domestic market for the APIs.

Related Videos: - https://bit.ly/2XVNXsY

 

Key players, such as Sun Pharma, Dr. Reddy’s, Cipla, Aurobindo Pharma, Lupin, etc., are being lured to increase their investment in the Indian API industry by providing them various lucrative offers.

Tags:-

#API #startupindia #APIBusiness #ActivePharmaceuticalIngredient  #Amoxicillin #azithromycint #ErythromycinStearate #ceftriaxone #cefoperazone #cefixime #amoxicillin #doxycycline #cephalexin #ciprofloxacin #clindamycin #metronidazole #azithromycine #Piperacillin #tazobactam #sulbactam #dexamethasone #prednisolone #Metformin #Gabapentin #clindamycin #Clindamycin #Streptomycin #Neomycin #Gentamycin #Doxycycline #Potassiumclavulanate #Oxytetracycline #Tetracycline #Clarithromycin #Betamethasone #Ciprofloxacin #Losartan #Telmisartan #Artesunate #Norfloxacin #Ofloxacin #Metronidazole #Sulfadiazine #Levofloxacin #Meropenem #Paracetamol #Tinidazole #Ornidazole #Ritonavir #Diclofenac Sodium #Aspirin #Levetiracetam #Carbidopa  #Levodopa #Carbamazepine #Oxcarbazepine #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness  #startups #business #covidbusiness #covid19 #covidsmallbusiness

 


Information

  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

ABOUT NPCS

 

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report,  Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Section of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

Our Detailed Project report aims at providing all the critical data required by any entrepreneur vying to venture into Project. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.

 


And before diversifying/venturing into any product, wish to study the following aspects of the identified product:


• Good Present/Future Demand
• Export-Import Market Potential
• Raw Material & Manpower Availability
• Project Costs and Payback Period


We at NPCS, through our reliable expertise in the project consultancy and market research field, Provides exhaustive information about the project, which satisfies all the above mentioned requirements and has high growth potential in the markets. And through our report we aim to help you make sound and informed business decision.

 

The report contains all the data which will help an entrepreneur find answers to questions like:

• Why I should invest in this project?
• What will drive the growth of the product?
• What are the costs involved?
• What will be the market potential?


The report first focuses on enhancing the basic knowledge of the entrepreneur about the main product, by elucidating details like product definition, its uses and applications, industry segmentation as well as an overall overview of the industry sector in India. The report then helps an entrepreneur identify the target customer group of its product. It further helps in making sound investment decision by listing and then elaborating on factors that will contribute to the growth of product consumption in India and also talks about the foreign trade of the product along with the list of top importing and top exporting countries. Report includes graphical representation and forecasts of key data discussed in the above mentioned segment. It further explicates the growth potential of the product.

The report includes other market data like key players in the Industry segment along with their contact information and recent developments. It includes crucial information like raw material requirements, list of machinery and manufacturing process for the plant. Core project financials like plant capacity, costs involved in setting up of project, working capital requirements, projected revenue and profit are further listed in the report.


Reasons for buying the report:

• This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, demand of the product and reasons for investing in the product.

• This report provides vital information on the product like its definition, characteristics and segmentation.

• This report helps you market and place the product correctly by identifying the target customer group of the product.

• This report helps you understand the viability of the project by disclosing details like raw materials required, manufacturing process, project costs and snapshot of other project financials.

• The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decision.

 

Our Approach:


• Our research reports broadly cover Indian markets, present analysis, outlook and forecast.

• The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players. 

• We use reliable sources of information and databases.  And information from such sources is processed by us and included in the report.

 

Our Market Survey cum Detailed Techno Economic Feasibility Report Contains following information:

 

 

Ø  Introduction

·         Project Introduction

·         Project Objective and Strategy

·         Concise History of the Product

·         Properties

·         BIS (Bureau of Indian Standards) Provision & Specification

·         Uses & Applications

 

Ø  Market Study and Assessment

·         Current Indian Market Scenario

·         Present Market Demand and Supply

·         Estimated Future Market Demand and Forecast

·         Statistics of Import & Export

·         Names & Addresses of Existing Units (Present Players)

·         Market Opportunity

 

Ø  Raw Material

·         List of Raw Materials

·         Properties of Raw Materials

·         Prescribed Quality of Raw Materials

·         List of Suppliers and Manufacturers

 

Ø  Personnel (Manpower) Requirements

·         Requirement of Staff & Labor (Skilled and Unskilled) Managerial, Technical, Office Staff and Marketing Personnel

 

Ø  Plant and Machinery

·         List of Plant & Machinery

·         Miscellaneous Items

·         Appliances & Equipments

·         Laboratory Equipments & Accessories

·         Electrification

·         Electric Load & Water

·         Maintenance Cost

·         Sources of Plant & Machinery (Suppliers and Manufacturers)

 

Ø  Manufacturing Process and Formulations

·         Detailed Process of Manufacture with Formulation

·         Packaging Required

·         Process Flow Sheet Diagram

 

Ø  Infrastructure and Utilities

·         Project Location

·         Requirement of Land Area

·         Rates of the Land

·         Built Up Area

·         Construction Schedule

·         Plant Layout and Requirement of Utilities

 

Project at a Glance

Along with financial details as under:

 

  •     Assumptions for Profitability workings

  •    Plant Economics

  •    Production Schedule

  •    Land & Building

            Factory Land & Building

            Site Development Expenses

  •    Plant & Machinery

             Indigenous Machineries

            Other Machineries (Miscellaneous, Laboratory etc.)

  •    Other Fixed Assets

            Furniture & Fixtures

            Pre-operative and Preliminary Expenses

            Technical Knowhow

            Provision of Contingencies

  •   Working Capital Requirement Per Month

             Raw Material

            Packing Material

            Lab & ETP Chemical Cost

           Consumable Store

  •   Overheads Required Per Month And Per Annum

         Utilities & Overheads (Power, Water and Fuel Expenses etc.)

             Royalty and Other Charges

            Selling and Distribution Expenses

  •    Salary and Wages

  •    Turnover Per Annum

  •   Share Capital

            Equity Capital

            Preference Share Capital

 

  •    Annexure 1:: Cost of Project and Means of Finance

  •    Annexure 2::  Profitability and Net Cash Accruals

                Revenue/Income/Realisation

                Expenses/Cost of Products/Services/Items

                Gross Profit

                Financial Charges     

                Total Cost of Sales

                Net Profit After Taxes

                Net Cash Accruals

  •   Annexure 3 :: Assessment of Working Capital requirements

                Current Assets

                Gross Working. Capital

                Current Liabilities

                Net Working Capital

                Working Note for Calculation of Work-in-process

  •    Annexure 4 :: Sources and Disposition of Funds

  •    Annexure 5 :: Projected Balance Sheets

                ROI (Average of Fixed Assets)

                RONW (Average of Share Capital)

                ROI (Average of Total Assets)

  •    Annexure 6 :: Profitability ratios

                D.S.C.R

                Earnings Per Share (EPS)

               

             Debt Equity Ratio

        Annexure 7   :: Break-Even Analysis

                Variable Cost & Expenses

                Semi-Var./Semi-Fixed Exp.

                Profit Volume Ratio (PVR)

                Fixed Expenses / Cost 

                B.E.P

  •   Annexure 8 to 11:: Sensitivity Analysis-Price/Volume

            Resultant N.P.B.T

            Resultant D.S.C.R

   Resultant PV Ratio

   Resultant DER

  Resultant ROI

          Resultant BEP

  •    Annexure 12 :: Shareholding Pattern and Stake Status

        Equity Capital

        Preference Share Capital

  •   Annexure 13 :: Quantitative Details-Output/Sales/Stocks

        Determined Capacity P.A of Products/Services

        Achievable Efficiency/Yield % of Products/Services/Items 

        Net Usable Load/Capacity of Products/Services/Items   

       Expected Sales/ Revenue/ Income of Products/ Services/ Items   

  •    Annexure 14 :: Product wise domestic Sales Realisation

  •    Annexure 15 :: Total Raw Material Cost

  •    Annexure 16 :: Raw Material Cost per unit

  •    Annexure 17 :: Total Lab & ETP Chemical Cost

  •    Annexure 18  :: Consumables, Store etc.,

  •    Annexure 19  :: Packing Material Cost

  •    Annexure 20  :: Packing Material Cost Per Unit

  •    Annexure 21 :: Employees Expenses

  •    Annexure 22 :: Fuel Expenses

  •    Annexure 23 :: Power/Electricity Expenses

  •    Annexure 24 :: Royalty & Other Charges

  •    Annexure 25 :: Repairs & Maintenance Exp.

  •    Annexure 26 :: Other Mfg. Expenses

  •    Annexure 27 :: Administration Expenses

  •    Annexure 28 :: Selling Expenses

  •    Annexure 29 :: Depreciation Charges – as per Books (Total)

  •   Annexure 30   :: Depreciation Charges – as per Books (P & M)

  •   Annexure 31   :: Depreciation Charges - As per IT Act WDV (Total)

  •   Annexure 32   :: Depreciation Charges - As per IT Act WDV (P & M)

  •   Annexure 33   :: Interest and Repayment - Term Loans

  •   Annexure 34   :: Tax on Profits

  •   Annexure 35   ::Projected Pay-Back Period And IRR